Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model
Date
2012
Authors
Schultheis, B.
Nijmeijer, B.
Yin, H.
Gosden, R.
Vaz de Melo, J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Leukemia Research, 2012; 36(3):271-274
Statement of Responsibility
Beate Schultheis, Bart A. Nijmeijer, H. Yin, Roger G. Gosden, Junia V. Melo
Conference Name
Abstract
Imatinib should be avoided in women planning to become pregnant or during pregnancy, due to a higher risk of congenital malformations. However, it is not known whether imatinib affects future potential for fertility. Here we analysed ovaries and testes from adult mice receiving imatinib, focusing on testicular and ovarian functions. Seven male and 7 female mice were orally treated with 150 mg/kg body weight/day imatinib for two months. No effects on folliculogenesis or spermatogenesis could be observed postmortem by histological examinations, suggesting that, at least in two mouse models of imatinib treatment this tyrosine kinase inhibitor does not reduce fertility.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2011 Elsevier Ltd. All rights reserved.